WellerS., BlumM., DoucetteM.Pharmacokinetics of the acyclovir pro-drug, valaciclovir after escalating single and multiple-dose administration to normal volunteers.Clin Pharmacol Ther1993; 54: 595–605.
2.
BoelaertJ., SchurgersM., DaneelsR.Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous peritoneal dialysis.J Antimicrob Chemother1987; 20: 69–76.
QuinnR., De MirandaP., GeraldL.A sensitive radio-immunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl) guanine].Anal Biochem1979; 98: 319–28.
5.
Pham-HuyC., StathoulopoulouF., SandoukP., SchermannJ., PalomboS., GirreC.Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution.J Chromatogr B Biomed Sci Appl1999; 732: 47–53.
6.
RoccoM., JordanJ., BurkartJ.Determination of peritoneal transport characteristics with 24-hour dialysate collections: Dialysis adequacy and transport test.J Am Soc Nephrol1994; 5: 1333–8.
7.
RippeB.Pathophysiological description of the ultra-structural changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis.Blood Purif1994; 12: 211–20.
8.
SpaiaS., ChristidouF., PangidisP.Variability of peritoneal protein loss in diabetic and nondiabetic patients on continuous ambulatory peritoneal dialysis.Perit Dial Int1993; 13(Suppl 2): S242–4.
9.
De VruehR., SmithP., LeeC.Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco X.J Pharmacol Exp Ther1998; 286: 1166–70.
